Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President

Rhea-AI Filing Summary

Q32 Bio Inc. reported that its CFO and President, Lee Kalowski, received an equity award of 53,250 shares of common stock in the form of restricted stock units. This is a compensation-related grant at a price of $0.00 per share, not an open‑market purchase.

The RSUs vest in four equal 25% installments starting six months after the February 24, 2026 grant date, then at 12, 24, and 36 months from that date. Each RSU converts into one share of common stock upon vesting. After this grant, Kalowski holds 89,193 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalowski Lee

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A(1)		53,250	A	$0	89,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.

	/s/ Eric Bell, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Q32 Bio (QTTB) disclose for Lee Kalowski?

Q32 Bio disclosed that CFO and President Lee Kalowski received a grant of 53,250 restricted stock units. The award is a compensation-related acquisition at $0.00 per share, not a market purchase, and increases his direct common stock holdings to 89,193 shares after the grant.

How many RSUs did Q32 Bio (QTTB) grant to its CFO and President?

Q32 Bio granted 53,250 restricted stock units to its CFO and President, Lee Kalowski. Each RSU represents a contingent right to receive one share of common stock, subject to the vesting schedule tied to specific time periods after the February 24, 2026 grant date.

What is the vesting schedule for Q32 Bio (QTTB) CFO Lee Kalowski’s RSUs?

The 53,250 RSUs granted to CFO Lee Kalowski vest in four equal 25% installments. Vesting occurs 6, 12, 24, and 36 months from the February 24, 2026 grant date, with each vested RSU delivering one share of Q32 Bio common stock upon settlement.

Did Q32 Bio (QTTB) CFO Lee Kalowski buy or sell shares on the market?

The filing shows no open-market buying or selling by CFO Lee Kalowski. Instead, it reports a grant of 53,250 restricted stock units as compensation at $0.00 per share, which is categorized as an acquisition through an award rather than a market transaction.

What are CFO Lee Kalowski’s Q32 Bio (QTTB) holdings after the RSU grant?

After the reported RSU grant, CFO and President Lee Kalowski holds 89,193 shares of Q32 Bio common stock directly. This total reflects his ownership following the 53,250-share restricted stock unit award disclosed in the Form 4 insider transaction report.